Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 13, 2022

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
JAMA 2022 Sep 27;328(12)1223-1232, Y Cheng, L Han, L Wu, J Chen, H Sun, G Wen, Y Ji, M Dvorkin, J Shi, Z Pan, J Shi, X Wang, Y Bai, T Melkadze, Y Pan, X Min, M Viguro, X Li, Y Zhao, J Yang, T Makharadze, E Arkania, W Kang, Q Wang, J Zhu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading